Leniolisib

Brand names: Joenja · Active ingredient: Leniolisib Phosphate

In short: JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater. (1)

Forms & strengthsTablets: 40 mg: Pink, round, biconvex, beveled edge tablet with 40 on one side and LNB on the other side 50 mg: Brownish red, round, biconvex, beveled edge tablet with 50 on one side and LNB on the other side 70 mg: Yellow, oval, biconvex, beveled edge tablet …
LabelPharming Healthcare Inc.
Label updatedOct 05, 2026

What is Leniolisib used for?

JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater. (1)

Leniolisib dosage

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA .

The recommended dosage is based on weight as provided in Table 1.

Administer JOENJA orally twice daily approximately 12 hours apart, with or without food.

Age | Patient's Body Weight | Recommended Oral Dosage

4 years to less than 12 years of age | 27 kg to less than 38 kg | 40 mg twice daily

38 kg to less than 45 kg | 50 mg twice daily

45 kg or greater | 70 mg twice daily

12 years of age and older | Any weight | 70 mg twice daily

Missed Dose(s)

Advise patients that if a dose is missed by more than 6 hours, wait and take the next dose at the usual time.

Advise patients that if vomiting occurs within 1 hour after taking JOENJA, take JOENJA as soon as possible. If vomiting occurs more than 1 hour after dosing, wait and take the next dose at the usual time.

How to take Leniolisib — instructions & advice from the label

Embryo-Fetal Toxicity

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy .

Advise females of reproductive potential to use highly effective contraception during treatment with JOENJA and for 1 week after the last dose .

Vaccinations

Instruct patients to inform the healthcare providers that they are taking JOENJA prior to a potential vaccination .

Risk of Hypersensitivity Reactions, Including Anaphylaxis

Advise patients to discontinue JOENJA and to seek immediate medical attention if they develop any signs and symptoms of serious allergic reactions .

Lactation

Advise women not to breastfeed during treatment with JOENJA and for 1 week after the last dose .

Administration

Advise patients JOENJA may be taken with or without food .

Instruct patients that if they miss a dose by more than 6 hours, skip the missed dose. Advise patients to take the next dose as scheduled .

Instruct patients that if vomiting occurs within 1 hour after taking JOENJA, take a dose as soon as possible . …

Warnings & precautions

Do not take this medicine if: None.

Based on findings in animals, JOENJA may cause fetal harm when administered to a pregnant woman. Administration of leniolisib to rats and rabbits during the period of organogenesis caused embryo-fetal toxicity including malformations at exposures that were 2-6 times higher than the maximum recommended human dose (MRHD) in APDS patients based on AUC comparisons. Verify the pregnancy status of patients of reproductive potential prior to starting treatment. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use highly effective contraception during treatment and for 1 week after the last dose .

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Hypersensitivity reaction(s), including anaphylaxis, have been reported in the postmarketing setting. If a clinically significant hypersensitivity reaction occurs, discontinue JOENJA and institute appropriate therapy .

Leniolisib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Risk of Hypersensitivity Reactions, Including Anaphylaxis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Patients 12 Years of Age and Older with APDS

The safety of JOENJA reflects exposure based on 38 adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) from the placebo-controlled portion of Study 2201 and additional open-label clinical safety data. Thirty-seven of 38 patients received JOENJA 70 mg orally twice daily for at least 25 weeks and 66% were exposed for 96 weeks or longer. Median duration of JOENJA treatment was approximately 2 years, and 4 patients had more than 5 years of JOENJA exposure.

The data below are based on the 12-week, placebo-controlled portion of Study 2201 in which either JOENJA 70 mg (N=21) or placebo (N=10) was administered twice daily to patients with APDS. Demographics of the patients who participated in this study are summarized in Clinical Studies . …

Drug interactions

Strong CYP3A4 Inhibitors

Concomitant use of JOENJA with strong CYP3A4 inhibitors should be avoided.

JOENJA is a substrate of CYP3A4. Leniolisib exposure was increased 2-fold when co-administered with itraconazole, a strong CYP3A4 inhibitor .

Strong and Moderate CYP3A4 Inducers

Concomitant use of JOENJA with strong and moderate CYP3A4 inducers should be avoided.

JOENJA is a substrate of CYP3A4. Concomitant use of strong and moderate CYP3A4 inducers may result in reduced leniolisib exposure and thus reduced leniolisib efficacy .

Concomitant use of JOENJA with BCRP, OATP1B1, and OATP1B3 substrates should be avoided.

JOENJA is an inhibitor of BCRP, OATP1B1, and OATP1B3 transporters. Administration of JOENJA increases exposure of BCRP, OATP1B1, and OATP1B3 substrates , which may increase the risk of adverse reactions related to these substrates.

About this medicine

Leniolisib is a kinase inhibitor. The chemical name for leniolisib phosphate is 1-[(3S)-3-[[5,6,7,8-Tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin-4-yl]amino]-1-pyrrolidinyl]-1-propanone phosphate (1:1).

Leniolisib phosphate has the following structural formula:

The molecular formula is C21H25F3N6O2•H3PO4 and the molecular weight is 450.47 g/mol for the free base, 548.46 g/mol for the phosphate salt.

Leniolisib phosphate is a white to yellowish to yellowish-greenish powder. The aqueous solubility of leniolisib phosphate is pH dependent with decreasing solubility observed with increasing pH.

JOENJA film-coated tablets are for oral administration and are available in 40 mg, 50 mg, and 70 mg strengths of leniolisib, equivalent to 48.72 mg, 60.90 mg, and 85.26 mg leniolisib phosphate, respectively. The tablet core contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID eefbcef8-2130-4654-8f29-b58077e08212. Read the full official label on DailyMed.